Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials

Primo N Lara, Debora A Paterniti, Christine Chiechi, Corinne Turrell, Claudia Morain, Nora Horan, Lisa Montell, Jose Gonzalez, Sharon Davis, Ari Umutyan, Cynthia L. Martel, David R Gandara, Theodore Wun, Laurel A Beckett, Moon S Chen

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Purpose: Annually, only 3% of patients participate in cancer clinical trials (CCTs). Barriers to accrual include lack of CCT awareness and uncertain third-party payer coverage. In January 2002, a California law (Senate Bill 37 [SB37]) required all third-party payers to reimburse patient care costs related to CCTs. We evaluated the level of awareness of patients and/or their family members/friends regarding CCTs and SB37. Methods: We used both a written survey for patients and/or their family members and friends seen in oncology clinics, and a verbal telephone version for Cancer Information Service callers. We tested for correlations between CCT awareness and SB37 knowledge, and willingness to participate in CCTs. Results: Of 1,188 respondents, 59% were aware of CCTs, 19% knew of SB37, and 36% were very likely to consider a CCT. There were significant positive correlations between CCT awareness and willingness to participate (P < .001, Spearman), and between SB37 knowledge and willingness to participate (P = .001, Pearson χ2). Reduced awareness was seen in respondents who were either black or African American (odds ratio [OR], 0.44; P = .004), Hispanic (OR, 0.56; P = .03), had an annual income less than $25,000 (OR, 0.38; P < .001), or had less than a college degree (OR, 0.12 to 0.53; P < .001 to .013). Reduced willingness to participate in CCTs was seen in black or African American participants (OR, 0.38; P < .001), Asians (OR, 0.44; P < .006), or respondents aged 18 to 24 years (OR, 0.35; P = .002). Conclusion: These results support the hypothesis that improving CCT awareness and SB37 knowledge especially among lower income, less educated, and minority patients, may potentially overcome barriers to participation and subsequently increase accrual in California.

Original languageEnglish (US)
Pages (from-to)9282-9288
Number of pages7
JournalJournal of Clinical Oncology
Volume23
Issue number36
DOIs
StatePublished - 2005

Fingerprint

Clinical Trials
Odds Ratio
Neoplasms
Health Insurance Reimbursement
African Americans
Information Services
Hispanic Americans
Telephone
Patient Care
Costs and Cost Analysis
Surveys and Questionnaires

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. / Lara, Primo N; Paterniti, Debora A; Chiechi, Christine; Turrell, Corinne; Morain, Claudia; Horan, Nora; Montell, Lisa; Gonzalez, Jose; Davis, Sharon; Umutyan, Ari; Martel, Cynthia L.; Gandara, David R; Wun, Theodore; Beckett, Laurel A; Chen, Moon S.

In: Journal of Clinical Oncology, Vol. 23, No. 36, 2005, p. 9282-9288.

Research output: Contribution to journalArticle

Lara, Primo N ; Paterniti, Debora A ; Chiechi, Christine ; Turrell, Corinne ; Morain, Claudia ; Horan, Nora ; Montell, Lisa ; Gonzalez, Jose ; Davis, Sharon ; Umutyan, Ari ; Martel, Cynthia L. ; Gandara, David R ; Wun, Theodore ; Beckett, Laurel A ; Chen, Moon S. / Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 36. pp. 9282-9288.
@article{87f293d37f064a3cae5a0997c0aa6066,
title = "Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials",
abstract = "Purpose: Annually, only 3{\%} of patients participate in cancer clinical trials (CCTs). Barriers to accrual include lack of CCT awareness and uncertain third-party payer coverage. In January 2002, a California law (Senate Bill 37 [SB37]) required all third-party payers to reimburse patient care costs related to CCTs. We evaluated the level of awareness of patients and/or their family members/friends regarding CCTs and SB37. Methods: We used both a written survey for patients and/or their family members and friends seen in oncology clinics, and a verbal telephone version for Cancer Information Service callers. We tested for correlations between CCT awareness and SB37 knowledge, and willingness to participate in CCTs. Results: Of 1,188 respondents, 59{\%} were aware of CCTs, 19{\%} knew of SB37, and 36{\%} were very likely to consider a CCT. There were significant positive correlations between CCT awareness and willingness to participate (P < .001, Spearman), and between SB37 knowledge and willingness to participate (P = .001, Pearson χ2). Reduced awareness was seen in respondents who were either black or African American (odds ratio [OR], 0.44; P = .004), Hispanic (OR, 0.56; P = .03), had an annual income less than $25,000 (OR, 0.38; P < .001), or had less than a college degree (OR, 0.12 to 0.53; P < .001 to .013). Reduced willingness to participate in CCTs was seen in black or African American participants (OR, 0.38; P < .001), Asians (OR, 0.44; P < .006), or respondents aged 18 to 24 years (OR, 0.35; P = .002). Conclusion: These results support the hypothesis that improving CCT awareness and SB37 knowledge especially among lower income, less educated, and minority patients, may potentially overcome barriers to participation and subsequently increase accrual in California.",
author = "Lara, {Primo N} and Paterniti, {Debora A} and Christine Chiechi and Corinne Turrell and Claudia Morain and Nora Horan and Lisa Montell and Jose Gonzalez and Sharon Davis and Ari Umutyan and Martel, {Cynthia L.} and Gandara, {David R} and Theodore Wun and Beckett, {Laurel A} and Chen, {Moon S}",
year = "2005",
doi = "10.1200/JCO.2005.02.6245",
language = "English (US)",
volume = "23",
pages = "9282--9288",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials

AU - Lara, Primo N

AU - Paterniti, Debora A

AU - Chiechi, Christine

AU - Turrell, Corinne

AU - Morain, Claudia

AU - Horan, Nora

AU - Montell, Lisa

AU - Gonzalez, Jose

AU - Davis, Sharon

AU - Umutyan, Ari

AU - Martel, Cynthia L.

AU - Gandara, David R

AU - Wun, Theodore

AU - Beckett, Laurel A

AU - Chen, Moon S

PY - 2005

Y1 - 2005

N2 - Purpose: Annually, only 3% of patients participate in cancer clinical trials (CCTs). Barriers to accrual include lack of CCT awareness and uncertain third-party payer coverage. In January 2002, a California law (Senate Bill 37 [SB37]) required all third-party payers to reimburse patient care costs related to CCTs. We evaluated the level of awareness of patients and/or their family members/friends regarding CCTs and SB37. Methods: We used both a written survey for patients and/or their family members and friends seen in oncology clinics, and a verbal telephone version for Cancer Information Service callers. We tested for correlations between CCT awareness and SB37 knowledge, and willingness to participate in CCTs. Results: Of 1,188 respondents, 59% were aware of CCTs, 19% knew of SB37, and 36% were very likely to consider a CCT. There were significant positive correlations between CCT awareness and willingness to participate (P < .001, Spearman), and between SB37 knowledge and willingness to participate (P = .001, Pearson χ2). Reduced awareness was seen in respondents who were either black or African American (odds ratio [OR], 0.44; P = .004), Hispanic (OR, 0.56; P = .03), had an annual income less than $25,000 (OR, 0.38; P < .001), or had less than a college degree (OR, 0.12 to 0.53; P < .001 to .013). Reduced willingness to participate in CCTs was seen in black or African American participants (OR, 0.38; P < .001), Asians (OR, 0.44; P < .006), or respondents aged 18 to 24 years (OR, 0.35; P = .002). Conclusion: These results support the hypothesis that improving CCT awareness and SB37 knowledge especially among lower income, less educated, and minority patients, may potentially overcome barriers to participation and subsequently increase accrual in California.

AB - Purpose: Annually, only 3% of patients participate in cancer clinical trials (CCTs). Barriers to accrual include lack of CCT awareness and uncertain third-party payer coverage. In January 2002, a California law (Senate Bill 37 [SB37]) required all third-party payers to reimburse patient care costs related to CCTs. We evaluated the level of awareness of patients and/or their family members/friends regarding CCTs and SB37. Methods: We used both a written survey for patients and/or their family members and friends seen in oncology clinics, and a verbal telephone version for Cancer Information Service callers. We tested for correlations between CCT awareness and SB37 knowledge, and willingness to participate in CCTs. Results: Of 1,188 respondents, 59% were aware of CCTs, 19% knew of SB37, and 36% were very likely to consider a CCT. There were significant positive correlations between CCT awareness and willingness to participate (P < .001, Spearman), and between SB37 knowledge and willingness to participate (P = .001, Pearson χ2). Reduced awareness was seen in respondents who were either black or African American (odds ratio [OR], 0.44; P = .004), Hispanic (OR, 0.56; P = .03), had an annual income less than $25,000 (OR, 0.38; P < .001), or had less than a college degree (OR, 0.12 to 0.53; P < .001 to .013). Reduced willingness to participate in CCTs was seen in black or African American participants (OR, 0.38; P < .001), Asians (OR, 0.44; P < .006), or respondents aged 18 to 24 years (OR, 0.35; P = .002). Conclusion: These results support the hypothesis that improving CCT awareness and SB37 knowledge especially among lower income, less educated, and minority patients, may potentially overcome barriers to participation and subsequently increase accrual in California.

UR - http://www.scopus.com/inward/record.url?scp=33644825132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644825132&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.02.6245

DO - 10.1200/JCO.2005.02.6245

M3 - Article

C2 - 16361626

AN - SCOPUS:33644825132

VL - 23

SP - 9282

EP - 9288

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -